Lachy Mclean
Overview
Explore the profile of Lachy Mclean including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
366
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karsdal M, Rovati L, Tambiah J, Kubassova O, Ladel C, Berenbaum F, et al.
Osteoarthr Cartil Open
. 2025 Mar;
7(2):100572.
PMID: 40083835
Objective: The inflammatory endotype is arguably one of the most well-established endotype in osteoarthritis (OA). While endotyping holds promise for advancing drug development, numerous potential challenges must be considered, addressed...
2.
Esfandiari E, Chen M, Smithson G, Blair D, Faessel H, Wagner J, et al.
Clin Transl Sci
. 2021 Mar;
14(3):820-828.
PMID: 33650758
Bruton's tyrosine kinase (BTK) is a target for treatment of hematologic malignancies and autoimmune diseases. TAK-020 is a highly selective covalent BTK inhibitor that inhibits both B cell receptor and...
3.
Fedyk E, Zhao L, Koch A, Smithson G, Estevam J, Chen G, et al.
Br J Clin Pharmacol
. 2020 Feb;
86(7):1314-1325.
PMID: 32045493
Aims: This investigation characterised tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 antibody TAK-079. Methods: A randomised, double-blind, placebo-controlled trial of a single intravenous (i.v.) infusion or subcutaneous (s.c.) injection of...
4.
Korver W, Carsillo M, Yuan J, Idamakanti N, Wagoner M, Shi P, et al.
J Pharmacol Exp Ther
. 2019 May;
370(2):182-196.
PMID: 31085699
Ectoenzyme CD38 is increased on lymphocytes in response to an antigenic challenge and it is hypothesized that targeting these activated lymphocytes could ameliorate pathologic activities in autoimmune diseases. The cynomolgus...
5.
Gunawardhana L, Mclean L, Punzi H, Hunt B, Palmer R, Whelton A, et al.
J Am Heart Assoc
. 2017 Nov;
6(11).
PMID: 29102979
Background: Hyperuricemia is associated with hypertension, with elevated serum uric acid levels postulated to have a causal role in the development of hypertension. Consequently, serum uric acid reduction may help...
6.
Goldfarb D, MacDonald P, Gunawardhana L, Chefo S, Mclean L
Clin J Am Soc Nephrol
. 2013 Aug;
8(11):1960-7.
PMID: 23929928
Background And Objectives: Higher urinary uric acid excretion is a suspected risk factor for calcium oxalate stone formation. Febuxostat, a xanthine oxidoreductase inhibitor, is effective in lowering serum urate concentration...
7.
Naik H, Wu J, Palmer R, Mclean L
Br J Clin Pharmacol
. 2012 Jan;
74(2):327-35.
PMID: 22242967
Aims: To determine the effect of febuxostat on cytochrome P450 2C8 (CYP2C8) activity using rosiglitazone as a CYP2C8 substrate. Methods: Healthy subjects received febuxostat 120 mg daily (regimen A) or...
8.
Segal B, Bowman S, Fox P, Vivino F, Murukutla N, Brodscholl J, et al.
Health Qual Life Outcomes
. 2009 May;
7:46.
PMID: 19473510
Objective: To assess the health related quality of life of patients with primary Sjögren's Syndrome (PSS) in a large US sample. Methods: Questionnaires were mailed to 547 patients with a...
9.
Fox P, Bowman S, Segal B, Vivino F, Murukutla N, Choueiri K, et al.
J Am Dent Assoc
. 2008 Dec;
139(12):1592-601.
PMID: 19047665
Background: In small studies, investigators have described oral features and their sequelae in primary Sjögren syndrome (PSS), but they have not provided a full picture of the aspects and implications...
10.
Simkins H, Merriman M, Highton J, Chapman P, ODonnell J, Jones P, et al.
Arthritis Rheum
. 2005 Jun;
52(7):2222-5.
PMID: 15986352
No abstract available.